Global longitudinal strain can predict heart failure exacerbation in stable outpatients with ischemic left ventricular systolic dysfunction

Damian Kaufmann\textsuperscript{1,\*}, Małgorzata Szwoch\textsuperscript{1,\*}, Joanna Kwiatkowska\textsuperscript{2,\*}, Grzegorz Raczak\textsuperscript{1,\*}, Ludmiła Daniłowicz-Szymanowicz\textsuperscript{1,\*}

1 Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdańsk, Poland,
2 Department of Pediatric Cardiology and Congenital Heart Defect, Medical University of Gdansk, Gdańsk, Poland

\* These authors contributed equally to this work.
\* d.kaufmann@gumed.edu.pl

Abstract

Background
Despite advancements in pharmacological and device-based treatment, heart failure (HF) continues to impose an enormous burden for health care system worldwide. Decompensation of HF is one of the main causes of hospitalization, therefore the identification of patients with the highest risk of such complication is still of great clinical importance. The prognostic significance and utility of global longitudinal strain (GLS) has been previously studied in patients with the broad spectrum of cardiovascular diseases in various endpoints, however its role in assessing the risk of hospitalization due to HF exacerbation of optimally treated outpatients has not been fully explored. Therefore, the aim of the study was to verify whether the GLS of the left ventricle (LV) derived by 2D speckle tracking echocardiography has, independently of other well-known clinical parameters, an additional impact on the risk of HF decompensation in stable patients with LV systolic dysfunction of ischemic origin.

Methods
In 193 clinically stable HF outpatients with LV ejection fraction (LVEF) $\leq$ 50%, GLS, additionally to other clinical parameters, was analyzed. During 34 (14–71) months of follow-up, 58 patients were hospitalized due to HF decompensation due to HF decompensation (EVENT).

Results
EVENT was significantly associated with age, QRS width, NYHA functional class, left atrium diameter, LV systolic and diastolic volume, LVEF, hemoglobin, brain natriuretic peptide, diuretic treatment, absence of beta-blockers, impaired renal function and history of diabetes in univariate Cox analyzes. GLS with pre-specified cut-off value of -9.4% was also significantly associated with the EVENT (HR 15.16; 95% CI 1.81–126.91). After adjusting for above-mentioned parameters GLS was still a significant predictor of hospitalization due to HF decompensation.
Conclusions
GLS measurement can provide incremental information on the risk of HF decompensation in stable outpatients with LV systolic dysfunction of ischemic origin.

Background
Constantly rising heart failure (HF) prevalence is a major clinical and public health concern. Despite compelling advancements in pharmacological and device-based treatment of HF, the mortality is still high [1, 2]. Coronary artery disease is a major risk factor for the incidence and decompensation of HF, which is the leading cause of hospitalizations, resulting in more than 1 million admissions in both the United States and Europe [3, 4]. From the clinical point of view, it seems crucial to identify the patients with the highest risk of such events and ensure that they receive expanded ambulatory care, which would translate into a reduced number of hospitalizations.

Over the years, many prognostic risk factors for HF exacerbation have been identified, including clinical, laboratory and echocardiographic parameters. Among the clinical parameters, the well-known are: new coronary events, poorly controlled hypertension, both ventricular and supraventricular arrhythmias with rapid ventricular rate, infections—especially respiratory system, high NYHA functional class, short distance in a 6-minute walk test, the presence of comorbidities, in particular: coronary artery disease, diabetes, renal failure, anemia and depression. In the group of laboratory parameters, increased levels of natriuretic peptides, troponins, catecholamine’s, urea, creatinine and low sodium levels have high prognostic value. In addition, one should not forget about other sociodemographic factors such as: age, marital status, compliance with dietary and therapeutic recommendations [5–9]. Many prior publications emphasize the usefulness of left ventricular (LV) ejection fraction (LVEF) assessment, which was considered one of the most important risk factors for morbidity and mortality. Nevertheless better parameters are still sought. Two-dimensional speckle tracking echocardiography (2D STE) opens new diagnostic possibilities as a valuable tool to assess LV function. LV global longitudinal strain (GLS) has emerged as a parameter which is more sensitive and objective than LVEF in evaluation of LV abnormalities [10, 11]. This was firmly established in various studies as a reliable indicator of prognosis for the broad spectrum of cardiovascular diseases [12–19]. However, these studies were primarily focused on other endpoints than HF decompensation. Therefore, the aim of our study was to verify whether GLS of the LV derived by 2D STE provides, independently of other well-known clinical parameters, an additional impact on the risk of hospitalization due to HF decompensation in clinically stable outpatients with LV systolic dysfunction of ischemic origin.

Methods
Study design and patient population
Between October 2009 and October 2018 we prospectively enrolled consecutive stable patients with ischemic HF and LVEF ≤ 50%. The protocol of the study was approved by the Local Ethics Committee of the Medical University of Gdansk. Several clinical parameters were taken into account: a comprehensive baseline clinical history and physical examination, 12-lead ECG, routine laboratory blood tests and 2D-transthoracic echocardiography parameters, medical treatment and concomitant diseases. All patients had sinus rhythm and were clinically

Global longitudinal strain can predict heart failure exacerbation
stable for at least 3 months before the enrollment. Patients received optimal medical therapy and coronary revascularization according to current guidelines [20–23]. The exclusion criteria were: age < 18 years, permanent atrial fibrillation/flutter, ventricular paced rhythm, NYHA functional class IV, clinical features of coronary instability at the moment of enrolment, a revascularization (coronary angioplasty or/and surgery by-pass) within 3 months prior to the study, or incomplete coronary revascularization status (scheduled control coronary angiography, coronary angioplasty or surgery by-pass), and non-cardiologic comorbidities with potential unfavorable effect on survival.

**Echocardiography**

Transthoracic echocardiography was performed in patients in the left lateral decubitus position using a GE VIVID E9 ultrasound system (GE Ultrasound, Horten, Norway) equipped with phased-array transducer (M5S). Data were acquired from parasternal long- and short-axis views and the three standard apical views. For each view, cine loops were obtained by recording 3 consecutive heart cycles. Grayscale recordings were optimized for LV evaluation at a frame rate of 50–80 frames per second. All echocardiograms were stored digitally and analyzed with offline software on EchoPAC workstation (v201, GE Healthcare, Horten, Norway). Standard echocardiographic parameters such as: LV end-diastolic (EDV) and end-systolic (ESV) volume, left atrium diameter (LADs) were analyzed according to the principles described in the recommendations [24, 25]. LVEF was measured by Simpson’s biplane method.

**Analysis of GLS.** LV longitudinal function was assessed by the semiautomatic algorithm (Automated Function Imaging, GE, Horten, Norway). Briefly, three myocardial markers were placed in an end-diastolic frame in the apical 4-, 2- and 3-chamber views, respectively. The software automatically tracked the contour of the myocardium throughout the heart cycle to cover the entire thickness of the LV wall. Adequate tracking could be verified in real time and corrected by adjusting the region of interest or by manually correcting the contour to ensure optimal tracking. The value of peak GLS derived by 2D STE was analyzed from three apical views and calculated in the 17 segments (6 basal, 6 mid, 4 apical and the apex) in relation to the strain magnitude at aortic valve closure (identified on continuous wave Doppler recording through the aortic valve in 5-chamber view) [26]. The authors established that in the present study the higher absolute value of peak GLS (more negative) is assumed to be as better, and the value closer to zero is described as worse.

**Follow-up**

All patients were followed-up at the University outpatient clinic every 6 months, or earlier if it was clinically required. The primary endpoint was hospitalization due to HF exacerbation (worsening signs of LV or right ventricular failure resulting in administration of intravenous diuretics) including those with fatal outcome (EVENT). The first episode of the EVENT was the end of follow-up period for a given patient. None of the patients were lost during the follow up.

**Statistics**

Continuous data are presented as the median (25th - 75th percentiles), or numbers (n) and percentages (%). Comparisons between EVENT(+) and EVENT(-) group were made with the Fisher’s exact test, U Mann-Whitney’s test or paired Student’s t-test. An association between the analyzed parameters and the endpoint was assessed using the Cox hazard models. The accuracy of pre-specified cut-off values for analyzed parameters and their association as potential predictors of the study endpoint was determined by area (AUC) under the receiver-
operating characteristic (ROC) curve. The time course of the endpoint, stratified according to
the established cut-off value for GLS, was estimated using the Kaplan-Meier method, and the
association between compared groups was estimated by the log-rank test. All the results were
considered statistically significant at $p \leq 0.05$. The statistical analysis was conducted with STATISTICA 9.0 (StatSoft, Tulsa OK, USA) and R 2.15.2.

Results

Clinical characteristics of the studied patients

Finally, 193 patients who met the inclusion criteria were enrolled. The average age of patients
was 64 (58–72) years, most of them were men (92%) and 91% underwent myocardial infarction,
average LVEF was 33% and GLS -12.3%. Concomitant diseases such as diabetes, hypertension, chronic kidney disease (in stage III or higher) and hypercholesterolemia were present in 53 (27%), 131 (68%), 43 (23%) and 132 (68%), respectively. Regarding pharmacotherapy, a significant proportion of patients received an optimal medical therapy. Baseline clinical, demographic and echocardiographic characteristics of the entire study group are presented in Table 1.

During 34 (14–71) month follow-up, 58 patients (30%) reached the study endpoint. Patients
from the EVENT(+) group were older, had a wider QRS complex, more advanced NYHA
functional class, lower hemoglobin, higher brain natriuretic peptide (BNP) level, they were
more likely to have diabetes, chronic kidney disease, they less likely used beta-blockers but
more often diuretics and digoxin. With regard to the echocardiographic examination, EVENT
(+) patients had larger LADs, greater EDV and ESV as well as lower LVEF and worse GLS:
respectively -8.4% (-8.9 --7.6) versus -12.6% (-14.9 --10.3) in EVENT(-) group ($p < 0.009$).
Fig 1 illustrates the example of GLS measurements with severely decreased average GLS value
of -7.8% in patient who was hospitalized due to HF decompensation. Fig 2 presents the exam-
ples of GLS measurements with moderately reduced average GLS value of -14% in patient who
didn’t reach study endpoint within follow-up period.

Predictors of hospitalization due to HF decompensation

Univariate Cox analyses revealed age, QRS, NYHA functional class III, hemoglobin, BNP,
LADs, EDV, ESV, LVEF, GLS, absence of beta-blockers, use of diuretics, diabetes and
GFR < 60 ml/min/1.73 m² as significant predictors of the EVENT. Pre-specified cut-off values
with the highest risk of the EVENT were: age ≥ 72 years, QRS ≥ 118 ms, hemoglobin < 14.8
g/dl, BNP ≥ 214 pg/ml, LAD ≥ 45 mm, EDV ≥ 166 ml, ESV ≥ 89 ml, LVEF < 32%, GLS ≥
-9.4% (Table 2).

ROC analysis identified GLS as the most accurate predictor of hospitalization due to HF
decompensation among all the studied continuous variables (AUC 0.81, hazard ratio [HR]
15.16, 95% confidence interval [CI] 1.81–126.91, $p < 0.012$) with high positive predictive value
(PPV) of 98%, whereas the rest of the analyzed parameters were characterized by lower dis-
criminatory powers as presented in Table 3.

GLS maintained its statistical significance as a predictor of the EVENT even after adjusting
to other above-mentioned parameters. Fig 3 illustrates Kaplan-Meier’s curve with the proba-
bility of the hospitalization due to HF exacerbation depending on pre-specified cut-off values
for GLS during follow-up period.
Table 1. Clinical, laboratory and echocardiographic characteristics of the study group and comparison between the EVENT(+) and EVENT(-) groups.

|                      | All n = 193 | EVENT(+) n = 58 | EVENT(-) n = 135 | p value |
|----------------------|-------------|-----------------|------------------|---------|
| Age (years)          | 64 (58–72)  | 67 (59–75)      | 64 (58–70)       | < 0.044 |
| Male, n (%)          | 177 (92)    | 53 (91)         | 124 (92)         | 1.000   |
| Myocardial infarction, n (%) | 175 (91) | 51 (88)         | 124 (92)         | 0.423   |
| Revascularization, n (%) | 173 (90) | 53 (91)         | 120 (89)         | 0.798   |
| QRS (ms)             | 90 (110–130)| 120 (100–160)   | 110 (90–120)     | < 0.001 |
| ICD, n (%)           | 115 (60)    | 50 (86)         | 65 (48)          | < 0.001 |
| NYHA I, n (%)        | 17 (9)      | 10 (17)         | 7 (5)            | < 0.011 |
| NYHA class           |             |                 |                 | < 0.001 |
| NYHA II, n (%)       | 34 (18)     | 5 (9)           | 29 (21)          |         |
| NYHA III, n (%)      | 127 (66)    | 35 (60)         | 92 (68)          |         |
| Laboratory parameters|             |                 |                 |         |
| Hemoglobin (g/dl)    | 14 (13–15)  | 13.8 (12.6–14.5)| 14.1 (13.7–14.8)| <0.049  |
| BNP (pg/ml)          | 108 (77–300)| 232 (104–1046)  | 104 (64–200)     | < 0.018 |
| Echocardiographic parameters |       |                 |                 |         |
| LADs (mm)            | 45 (41–48)  | 46 (43–50)      | 44 (40–48)       | < 0.005 |
| EDV (ml)             | 157 (125–200)| 170 (136–243)  | 153 (114–197)    | < 0.029 |
| ESV (ml)             | 99 (77–134) | 120 (96–171)    | 88 (69–127)      | < 0.001 |
| LVEF (%)             | 33 (27–40)  | 28 (23–33)      | 35 (30–40)       | < 0.001 |
| GLS (%)              | -12.3       | -8.4 (8.9–7.6)  | -12.6 (14.9–10.3)| < 0.009 |
| Medications          |             |                 |                 |         |
| beta-adrenolytics, n (%) | 184 (95) | 52 (90)         | 132 (98)         | < 0.023 |
| ACE-inhibitor or ARB, n (%) | 178 (92) | 55 (95)         | 123 (91)         | 0.559   |
| spironolactone/eplerenone, n (%) | 100 (52) | 31 (53)         | 69 (51)          | 0.875   |
| antiplatelet therapy, n (%) | 175 (91) | 51 (88)         | 124 (92)         | 0.423   |
| statins, n (%)       | 174 (90)    | 55 (95)         | 119 (88)         | 0.193   |
| digoxin, n (%)       | 6 (3)       | 5 (9)           | 1 (1)            | < 0.010 |
| diuretics, n (%)     | 89 (46)     | 38 (66)         | 51 (38)          | < 0.001 |
| Concomitant diseases |             |                 |                 |         |
| Arterial hypertension, n (%) | 131 (68) | 41 (71)         | 90 (67)          | 0.618   |
| Diabetes, n (%)      | 53 (27)     | 26 (45)         | 27 (20)          | < 0.001 |
| GFR < 60 ml/min/1.73 m², n (%) | 43 (22) | 25 (43)         | 18 (13)          | < 0.001 |
| Hypercholesterolemia, n (%) | 132 (68) | 39 (67)         | 93 (69)          | 0.867   |
| History of atrial fibrillation/flutter, n (%) | 41 (21) | 17 (29)         | 24 (18)          | 0.085   |
| Smoking, n (%)       | 142 (74)    | 44 (76)         | 98 (73)          | 0.723   |

Abbreviations: ACE–angiotensin converting enzyme, ARB–angiotensin receptor blocker; BNP–brain natriuretic peptide; CRT-D–implantable cardioverter defibrillator with cardiac resynchronization therapy; LADs–left atrium diameter; LVEF–left ventricular ejection fraction; EDV–left ventricular end-diastolic volume; ESV–left ventricular end-systolic volume; GFR–glomerular filtration rate; GLS–global longitudinal strain; ICD–implantable cardioverter defibrillator; MI–myocardial infarction; NYHA–classification according the New York Heart Association; QRS–QRS complex width

*p value for comparison between EVENT(+) and EVENT(-) groups

https://doi.org/10.1371/journal.pone.0225829.t001
Discussion

In this study, we proved that GLS with a cut-off value of $\pm 9.4\%$ is a statistically significant indicator of hospitalization due to HF decompensation, independent of other known risk factors in a well-defined group of stable individuals with ischemic cardiomyopathy with LVEF up to 50% who were optimally treated. In our opinion, assessment of GLS in clinical practice...
seems to be useful in identifying which patients should receive expanded ambulatory care to reduce the risk of HF exacerbations.

The role of GLS as a marker of cardiovascular events has been studied extensively in different groups of patients with regard to various endpoints [16, 27–30]. For example, in the study by Cho G et al., GLS was proved to be a predictor of the composite endpoint (cardiac mortality and HF exacerbations) in acute HF patients [27]. Nahum J et al., established the usefulness of GLS in the patients with chronic HF, but contrary to our study, they included patients with diverse HF etiology [28]. Buggey J et al., demonstrated the relationship between GLS and mortality or hospitalization for HF exacerbation in patients with acute HF and preserved EF (≥ 50%), however, this relationship was noted only in short-term observation [29].

GLS cut-off value of ≥ -9.4% determined in the present study in HF patients with LVEF up to 50% is within the range of values presented by other authors, varying from about -7% to -14% [13, 31–34]. The value of this parameter is usually better in groups of patients with higher LVEF and worse in those with lower LVEF.

Table 2. Results of Cox proportional hazard regression analysis for analyzed parameters and their pre-specified cut-off values as predictors of the EVENT during follow-up period.

| Parameter                      | Univariate analysis | p       |
|--------------------------------|---------------------|---------|
|                                | HR                  | 95% CI  |
| Age (years)                    | 1.05                | 1.01–1.08 | < 0.005 |
| Age ≥ 72 (years)               | 2.48                | 1.46–4.23 | < 0.001 |
| QRS (ms)                       | 1.01                | 1–1.02   | < 0.004 |
| QRS ≥ 118 (ms)                 | 1.99                | 1.14–3.49 | < 0.016 |
| NYHA class III                 | 2.35                | 1.34–4.13 | < 0.003 |
| Hemoglobin (g/dl)              | 0.82                | 0.69–0.98 | < 0.029 |
| Hemoglobin < 14.8 (g/dl)       | 3.02                | 1.19–7.7  | < 0.002 |
| BNP (pg/ml)                    | 1.00                | 1–1      | < 0.004 |
| BNP ≥ 214 (pg/ml)              | 2.64                | 1.13–5.31 | < 0.006 |
| LAD (mm)                       | 1.07                | 1.02–1.12 | < 0.004 |
| LAD ≥ 45 (mm)                  | 2.08                | 1.18–3.68 | < 0.011 |
| EDV (ml)                       | 1.01                | 1–1.01   | < 0.021 |
| EDV ≥ 166 (ml)                 | 1.83                | 0.91–3.69 | < 0.089 |
| ESV (ml)                       | 1.01                | 1–1.01   | < 0.013 |
| ESV ≥ 89 (ml)                  | 2.64                | 1.01–6.87 | < 0.047 |
| LVEF (%)                       | 0.93                | 0.9–0.96  | < 0.001 |
| LVEF < 32 (%)                  | 2.76                | 1.55–4.9  | < 0.001 |
| GLS (%)                        | 1.32                | 1–1.74   | < 0.049 |
| GLS ≥ -9.4 (%)                 | 15.16               | 1.81–126.91 | < 0.012 |
| Absence of betablockers        | 4.21                | 1.76–10.9 | < 0.001 |
| Diuretics                      | 2.17                | 1.26–3.73 | < 0.005 |
| Diabetes                       | 2.45                | 1.46–4.14 | < 0.001 |
| GFR < 60 ml/min/1.73 m²         | 3.16                | 1.87–5.34 | < 0.001 |

Abbreviations: BNP–brain natriuretic peptide; CI–confidence interval; LADs–left atrium diameter; LVEF–left ventricular ejection fraction; EDV–left ventricular end-diastolic volume; ESV–left ventricular end-systolic volume; GFR–glomerular filtration rate; GLS–global longitudinal strain; HR–hazard ratio; NYHA–classification according the New York Heart Association; QRS–QRS complex width

*p value for comparison between EVENT(+) and EVENT(-) groups

https://doi.org/10.1371/journal.pone.0225829.t002
Particularly noteworthy is that GLS cut-off value established in the present study was characterized by the highest discriminatory power in revealing the risk of HF decompensation. AUC for GLS \( \leq -9.4\% \) was 0.81, while for broadly acknowledge LVEF it was lower (0.76). Furthermore, in the case of GLS values \( \leq -9.4\% \), the relative risk of hospitalization due to HF decompensation was 15 times higher, while for others at most 2–3 fold. It is also worth to emphasize the very high PPV of GLS (98%), which was the highest PPV of all analyzed parameters. Sensitivity and specificity of this parameter were also high (87% and 86%, respectively). Thereby, GLS proved to be the strongest indicator of HF decompensation in the group of stable patients with ischemic cardiomyopathy with LVEF \( \leq 50\% \). In addition, it is a quick and

| Parameters       | AUC | Characteristics (95% CI) | Predictive Value (95% CI) |
|------------------|-----|--------------------------|---------------------------|
|                  |     | Sensitivity (%) | Specificity (%) | Positive (%) | Negative (%) |
| Age \( \geq 72\) (years) | 0.59 | 80                     | 40                      | 76          | 46           |
| QRS \( \geq 118\) (ms)   | 0.67 | 61                     | 68                      | 82          | 43           |
| Hemoglobin \(< 14.8\) (g/dl) | 0.59 | 32                     | 88                      | 85          | 37           |
| BNP \( \geq 214\) (pg/ml) | 0.73 | 79                     | 56                      | 77          | 58           |
| LADs \( \geq 45\) (mm)   | 0.63 | 54                     | 67                      | 78          | 41           |
| EDV \( \geq 166\) (ml)   | 0.63 | 67                     | 58                      | 77          | 44           |
| ESV \( \geq 89\) (ml)    | 0.72 | 51                     | 85                      | 88          | 44           |
| LVEF \(< 32\) (%)        | 0.76 | 67                     | 72                      | 85          | 49           |
| GLS \( \leq -9.4\) (%)    | 0.81 | 87                     | 86                      | 98          | 50           |

Abbreviations: AUC–area under curve; BNP–brain natriuretic peptide; CI–confidence interval; HGB–hemoglobin; LADs–left atrium diameter; LVEF–left ventricular ejection fraction; EDV–left ventricular end-diastolic volume; ESV–left ventricular end-systolic volume; GFR–glomerular filtration rate; GLS–global longitudinal strain; QRS–QRS complex width

https://doi.org/10.1371/journal.pone.0225829.t003

Fig 3. Kaplan-Meier curves illustrating probability of the hospitalization due to HF exacerbation after dichotomization according the pre-specified cut-off values for GLS during follow-up period.

https://doi.org/10.1371/journal.pone.0225829.g003
easy to obtain parameter, even at the patient’s bedside, more objective and not based on geometrical assumptions, as in case of LVEF. GLS seems to be considered as a standard parameter evaluated in patients with HF for identification the most at-risk persons requiring special care.

**Study limitations**

It was a small, single-center investigation and due to the relatively small number of patients, it was impossible to create a more stable subpopulation of patients who reached the endpoint, and thus the results need to be confirmed in a larger group of patients. Next, functional performance of the studied population was not evaluated [35] (for example by 6 minute walking test) and patients permanent atrial fibrillation were excluded from the study. Furthermore, other speckle tracking parameters, such as circumferential and radial strain, which are shown to be promising, were not evaluated [36]. Moreover, GLS was assessed using only one of the available vendor platforms, therefore the results may be slightly different from those received with alternative software algorithms [37].

**Conclusions**

GLS derived by 2D STE can provide, independently of other well-known clinical parameters, information on the risk of hospitalization due to HF decompensation in the stable outpatients with LV systolic dysfunction of ischemic origin. Decreased GLS with cut-off value of \(-9.4\%\) can identify the patients with the highest risk of such event, who require special care.

**Supporting information**

S1 File. Data set.
(PDF)

**Author Contributions**

**Conceptualization:** Damian Kaufmann, Ludmiła Danilowicz-Szymanowicz.

**Data curation:** Damian Kaufmann, Małgorzata Szwoch.

**Formal analysis:** Damian Kaufmann, Małgorzata Szwoch, Ludmiła Danilowicz-Szymanowicz.

**Investigation:** Damian Kaufmann, Małgorzata Szwoch, Ludmiła Danilowicz-Szymanowicz.

**Methodology:** Damian Kaufmann, Ludmiła Danilowicz-Szymanowicz.

**Project administration:** Grzegorz Raczak, Ludmiła Danilowicz-Szymanowicz.

**Resources:** Damian Kaufmann, Grzegorz Raczak, Ludmiła Danilowicz-Szymanowicz.

**Software:** Damian Kaufmann, Ludmiła Danilowicz-Szymanowicz.

**Supervision:** Joanna Kwiatkowska, Grzegorz Raczak.

**Validation:** Grzegorz Raczak.

**Visualization:** Damian Kaufmann, Ludmiła Danilowicz-Szymanowicz.

**Writing – original draft:** Damian Kaufmann, Małgorzata Szwoch, Ludmiła Danilowicz-Szymanowicz.

**Writing – review & editing:** Joanna Kwiatkowska, Grzegorz Raczak.
References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive Summary: Heart Disease and Stroke Statistics—2016 Update. Circulation. 2016; 133: 447–54. https://doi.org/10.1161/CIR.0000000000000366 PMID: 26811276

2. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3: 7. https://doi.org/10.15420/cfr.2016:25:2 PMID: 28785469

3. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2010; 8: 30–41. https://doi.org/10.1038/nrcardio.2010.165 PMID: 2106326

4. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart Failure–Associated Hospitalizations in the United States. J Am Coll Cardiol. 2013; 61: 1259–67. https://doi.org/10.1016/j.jacc.2012.12.038 PMID: 23500328

5. Daniłowicz-Szymanowicz L, Suchecka J, Niemirycz-Makurat A, Rozwadowska K, Raczk G. Auto-nomic Predictors of Hospitalization Due to Heart Failure Decompensation in Patients with Left Ventricular Systolic Dysfunction. PLOS ONE 2016; 11: e0152372. https://doi.org/10.1371/journal.pone.0152372 PMID: 27015089

6. Tomaszuk-Kazberuk A, Bolińska S, Młodawska E, Łopatowska P, Sobkowicz B, Musiał W. Does admission anaemia still predict mortality six years after myocardial infarction? Kardiol Pol. 2014; 72(6): 488–93. https://doi.org/10.5603/KP.a2014.0046 PMID: 24526561

7. Álvarez-Garcia J, Ferrer-go Gregori A, Puig T, Vázquez R, Pascual-Figal D, et al. A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE. Eur J Heart Fail. 2015; 17: 818–27. https://doi.org/10.1002/ejhf.287 PMID: 26011392

8. Ezekowitz J, O'Meara E, McDonald M, Abrams H, Chan M, Ducharme A et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017; 33(11): 1342–1433. https://doi.org/10.1016/j.cjca.2017.08.022 PMID: 29111106

9. Testa G, Della-Morte D, Cacciatore F, Gargiulo G, D'Ambrosio D, Galizia G, et al. Precipitating Factors in Younger and Older Adults with Decompensated Chronic Heart Failure: Are They Different? J Am Geriatr Soc. 2013; 61: 1827–8. https://doi.org/10.1111/jgs.12475 PMID: 24117301

10. Gorcsan J, Tanaka H. Echocardiographic assessment of myocardial strain. J Am Coll Cardiol. 2011; 58(14): 1401–13. https://doi.org/10.1016/j.jacc.2011.06.038 PMID: 21939821

11. Stanton T, Leano R, Marwick TH. Prediction of All-Cause Mortality From Global Longitudinal Speckle Strain. Circ Cardiovasc Imaging. 2009; 2: 356–64. https://doi.org/10.1161/CIRCIMAGING.109.862354 PMID: 19808623

12. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and Indications. J Am Soc Echocardiogr. 2011; 24:277–313. https://doi.org/10.1016/j.echo.2011.01.015 PMID: 21338865

13. Bertini M, Ng ACT, Antoni ML, Nucifora G, Ewe SH, Auger D, et al. Global Longitudinal Strain Predicts Long-Term Survival in Patients With Chronic Ischemic Cardiomyopathy. Circ Cardiovasc Imaging. 2012; 5: 383–91. https://doi.org/10.1161/CIRCIMAGING.111.970434 PMID: 22412068

14. Saito M, Okayama H, Yoshii T, Higashi H, Morioka H, Hiasa G, et al. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012; 13: 617–23. https://doi.org/10.1093/heartjnl/jer318 PMID: 22271116

15. Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Hassager C, et al. Global longitudinal strain can predict heart failure exacerbation. PLOS ONE | https://doi.org/10.1371/journal.pone.0225829 December 2, 2019 10 / 12

16. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014; 100: 1673–80. https://doi.org/10.1136/heartjnl-2014-305538 PMID: 24860005

17. Sengeløv M, Jørgensen PG, Jensen JS, Bruun NE, Olsen FJ, Fritz-Hansen T, et al. Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction. JACC Cardiovasc Imaging. 2015; 8: 1351–9. https://doi.org/10.1016/j.jcmg.2015.07.013 PMID: 26577264

18. Park JJ, Park J-B, Park J-H, Cho G-Y. Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure. J Am Coll Cardiol. 2018; 71: 1947–57. https://doi.org/10.1016/j.jacc.2018.02.064 PMID: 29724346
Global longitudinal strain can predict heart failure exacerbation

19. Zhang KW, French B, May Khan A, Plappert T, Fang JC, Swietzer NK, et al. Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure. J Am Heart Assoc. 2014;3. https://doi.org/10.1161/jaha.113.000550 PMID: 24419736

20. Fox K, Garcia M, Ardissino D, Buszman P, Cambi C, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–1381. https://doi.org/10.1093/eurheartj/ehl001 PMID: 16735367

21. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008†. Eur J Heart Fail. 2008; 10: 933–89. https://doi.org/10.1016/j.ejheart.2008.08.005 PMID: 18628676

22. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787–847. https://doi.org/10.1093/eurheartj/ehs005 PMID: 22611136

23. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016; 18: 80–262. https://doi.org/10.1002/ehj.28128 PMID: 27208619

24. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019; 32: 1–64. https://doi.org/10.1016/j.echo.2018.06.004 PMID: 30282592

25. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003 PMID: 25559473

26. Leitman M, Lysiansky M, Lysyansky P, Friedman Z, Tyomkin V, Fuchs T, et al. Circumferential and Longitudinal Strain in 3 Myocardial Layers in Normal Subjects and in Patients with Regional Left Ventricular Dysfunction. J Am Soc Echocardiogr. 2010; 23: 64–70. https://doi.org/10.1016/j.echo.2009.10.004 PMID: 2012496

27. Cho G-Y, Marwick TH, Kim H-S, Kim M-K, Hong K-S, Oh D-J. Global 2-Dimensional Strain as a New Prognosticator in Patients With Heart Failure. J Am Coll Cardiol. 2009; 54: 618–24. https://doi.org/10.1016/j.jacc.2009.04.061 PMID: 19660692

28. Nahum J, Bensaid A, Dussault C, Macron L, Clémence D, Bouhemad B, et al. Impact of Longitudinal Myocardial Dysfunction on the Prognosis of Chronic Heart Failure Patients. Circ Cardiovasc Imaging. 2010; 3: 249–56. https://doi.org/10.1161/CIRCIMAGING.109.910893 PMID: 20233858

29. Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, et al. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Fail. 2017; 4: 432–9. https://doi.org/10.1002/ehf2.12159 PMID: 29154416

30. Iacoviello M, Puzzovivo A, Guida P, Forleo C, Montillo F, Catanzaro R, et al. Independent Role of Left Ventricular Global Longitudinal Strain in Predicting Prognosis of Chronic Heart Failure Patients. Echocardiography. 2013; 30: 803–11. https://doi.org/10.1111/ech.12142 PMID: 23488596

31. Ernstbl M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, et al. Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2013; 61: 2365–73. https://doi.org/10.1016/j.jacc.2013.02.061 PMID: 23563128

32. Mignot A, Donal E, Darou F, Wam L, Hamon C, et al. Global Longitudinal Strain as a Major Predictor of Cardiac Events in Patients with Depressed Left Ventricular Function: A Multicenter Study. J Am Soc Echocardiogr. 2010; 23: 1019–24. https://doi.org/10.1016/j.echo.2010.07.019 PMID: 20810243

33. Kansal MM, Mansour IN, Ismail S, Bress A, Wu G, Mirza O, et al. Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients. Clin Cardiol. 2017; 40: 314–21. https://doi.org/10.1002/clc.22662 PMID: 28272832

34. Motoki H, Borowski AG, Shrestha K, Troughton RW, Tang WHW, Thomas JD, et al. Incremental Prognostic Value of Assessing Left Ventricular Myocardial Mechanics in Patients With Chronic Systolic Heart Failure. J Am Coll Cardiol. 2012; 60: 2074–81. https://doi.org/10.1016/j.jacc.2012.07.047 PMID: 23083779

35. Cacciatore F, Abete P, Mazzella F, Furgi G, Nicolino A, Longobardi G, et al. Six-minute walking test but not ejection fraction predicts mortality in elderly patients undergoing cardiac rehabilitation following
coronary artery bypass grafting. Eur J Prev Cardiol. 2012; 19(6): 1401–9. https://doi.org/10.1177/1741826711422991 PMID: 21933832

36. Hung C-L, Verma A, Uno H, Shin S-H, Bourgoun M, Hassanein AH, et al. Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. J Am Coll Cardiol. 2010; 56: 1812–22. https://doi.org/10.1016/j.jacc.2010.06.044 PMID: 21087709

37. Risum N, Ali S, Olsen NT, Jons C, Khouri MG, Lauridsen TK, et al. Variability of Global Left Ventricular Deformation Analysis Using Vendor Dependent and Independent Two-Dimensional Speckle-Tracking Software in Adults. J Am Soc Echocardiogr. 2012; 25: 1195–203. https://doi.org/10.1016/j.echo.2012.08.007 PMID: 22981228